MRC Centre for Reproductive Health
MRC Logo JAN 2019

Dr Veronique Miron

Research interest and grants.

Dr Veronique Miron

Senior Lecturer and Principal Investigator

Address

Street

The Queen’s Medical Research Institute
Edinburgh BioQuarter
47 Little France Crescent

City
Edinburgh
Post Code
EH16 4TJ

Biographical Information

Veronique Miron obtained her PhD in 2009 in Neurological Sciences from McGill University (Canada), funded by studentships from the Natural Sciences and Engineering Research Council and the Canadian Institutes of Health Research, and was awarded the European Charcot Foundation Young Investigator Award. Following a brief postodoc in Neuroimmunology at the Montreal Neurological Institute, she carried out a postdoc in Regenerative Medicine at The Scottish Centre for Regenerative Medicine, funded by the Multiple Sclerosis Society of Canada. She is now a Senior Lecturer in the MRC Centre for Reproductive Health and an MRC/ MS Society Career Development Fellow, leading a team of 5 researchers.

Veronique’s research focuses on investigating the regenerative properties of inflammation to drive central nervous system white matter regeneration, with implications for neurological disorders with high worldwide prevalence (such as cerebral palsy and MS).  She has >14 years of research experience in regenerative medicine, myelin biology and neuroimmunology, including proficiency developing and applying in vitro/ ex vivo/ in vivo modelling of neurological disease, transgenic approaches, advanced imaging platforms, high through-put imaging/analysis, and neuropathological analysis. She has authored 31 publications, including in Nature Neuroscience, Acta Neuropathologica, and Annals of Neurology.

She is an active champion of equal opportunity in research, heading the Athena Swan postgraduate working group, writing blogs on women in research, and chairing the Power Hour at the GRC Myelin conference. She is also the founder and organizer for Edinburgh’s first Microglia Club.

Research interests

Cerebral palsy is a lifelong disorder with no cure, incurred perinatally and characterized by severe motor impairments. The main contributor to the development of cerebral palsy is brain injury incurred in preterm and full-term infants, directed primarily at white matter (myelin) and the cells that make myelin, cells of the oligodendrocyte lineage. Current treatments aim to dampen injury and are only marginally effective at improving deficits due to their inability to promote myelin repair. Thus, there is a pressing need for the development of therapies for cerebral palsy that promote this repair thereby rescuing clinical deficits.

The research group is taking a novel approach to doing this by harnessing the regenerative properties of inflammation, in particular, macrophages (including CNS-resident microglia). Although macrophages have traditionally been implicated in inducing central nervous system injury, our recent studies show that anti-inflammatory macrophages drive myelin regeneration in the adult brain. Our overarching goal is to build on these findings to develop new strategies to promote myelin generation following developmental brain injury, by manipulating macrophage activation and identifying the regenerative factors they produce.

The main areas of research of our group are:

  • To characterize the role of microglia/ macrophage activation in perinatal brain injury & repair,
  • To elucidate the cellular and molecular mechanisms regulating microglia/ macrophage activation following injury and during repair of the central nervous system,
  • To compare the inflammatory and regenerative mechanisms following injury in developing vs adult central nervous system (e.g. MS),
  • To discover novel therapeutic targets by identifying microglia/ macrophage-derived regenerative factors.

Follow the Miron lab’s research interests and progress on twitter

Grants

  • Miron VE. MRC/ MS Society Career Development Award, £1,494,847. 2015-2020.
  • Miron VE. PhD studentship from NC3Rs, £90,000. 2019-2022.
  • Miron VE. PhD studentship from the UK Multiple Sclerosis Society, £94,725. 2017-2020.
  • Miron VE. Wellcome Trust Institutional Strategic Support Fund, £38,388. 2018-2019.
  • Miron VE, Norman JE, Gressens P. Action Medical Research, “Novel strategies to drive CNS repair following perinatal brain injury”, £199,356. 2015-2018.
  • Miron VE, BBSRC-GSK CASE studentship & grant, ‘Assessment of immunomodulatory compounds in driving macrophage activation in models of myelin injury and repair’, £96,126. 2014-2018.
  • Miron VE. RS MacDonald Trust, £60,000. 2014-2017.
  • Miron VE. Tommy’s the Baby Charity, £20,000. 2014.
  • Industry collaborations with: ReWind Therapeutics (2019), Clene Nanomedicine (2016-2017), Biogen (2014-2017), GSK (2014-2018), BVBioMed (2016), CDRD (2015)

Current lab members

Miron Lab Members 2017
  • Lindsey Forbes (postdoctoral fellow)
  • Rebecca Holloway (senior lab assistant)
  • Amy Lloyd (shared postdoctoral fellow with Josef Priller, DRI)
  • Niamh McNamara (Tissue Repair PhD student)
  • Irene Molina (MS Society PhD student)
  • Second supervisor to PhD students: Sarah Neely, Katie Smith, Clare Latta, Robert Shaw, Fenia Tsouki

Recent publications

  1. Lloyd AF, Davies CL, Holloway RK, Labrak Y, Ireland G, Carradori D, Dillenburg A, Borger E, Soong D, Richardson JC, Kuhlmann T, Williams A, Pollard JW, des Rieux A, Priller J, Miron VE (2019). Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nature Neuroscience. doi:10.1038/s41593-019-0418-z
  2. Dillenburg A, Ireland G, Holloway RK, Davies CL, Evans FL, Swire M, Bechler ME, Soong D, Yuen TJ, Su GH, Becher JC, Smith C, Williams A, Miron VE (2018). Activin receptors regulate the oligodendrocyte lineage in health and disease. Acta Neuropathologica. Feb 3. doi: 10.1007/s00401-018-1813-3
  3. Lloyd AF and Miron VE (in press). The pro-remyelination properties of microglia in the central nervous system. Nature Reviews Neurology.
  4. Boardman JP, Ireland G, Sullivan G, Pataky R, Fleiss B, Gressens P, Miron VE (2018). The cerebrospinal fluid inflammatory response to preterm birth. Frontiers in Physiology. Sep 12. doi: 10.3389/fphys.2018.01299
  5. Davies CL, Gyoneva S, Coulter A, Ransohoff R, Miron VE (2019). Cell isolation and RNA preparation from experimental focal remyelinating lesions. Methods in Molecular Biology, editors David Lyons and Linde Kegel.doi: 10.1007/978-1-4939-9072-6_2
  6. Lloyd AF, Davies CL, Miron VE (2017) Microglia: origins, homeostasis, and roles in repair. Current Opinion on Neurobiology, editors Beth Stevens and Alison Lloyd. 47: 113-120.
  7. Davies C, Miron VE (2016). Distinct origins, gene expression and function of microglia and monocyte-derived macrophages in CNS myelin injury and regeneration. Clinical Immunology. S1521-6616(16) 30142-30145.
  8. Lloyd AF, Miron VE (2016). Cellular and molecular mechanisms underpinning macrophage activation during remyelination. Frontiers in Cell and Developmental Biology (Molecular Medicine). Jun 21;4:60. doi: 10.3389/fcell.2016.00060. eCollection 2016.
  9. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, vWijngaarden AJ, Wajers AJ, Williams A, Franklin RJM, ffrench-Constant C (2013). M2 microglia/ macrophages drive oligodendrocyte differentiation during CNS remyelination. Nature Neuroscience. 16(9):1211-1218.